Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for Adult NHL
Stage is important in selecting a treatment for patients with non-Hodgkin lymphoma (NHL). Chest and abdominal computed tomography (CT) scans are usually part of the staging evaluation for all lymphoma patients. The staging system is similar to the staging system used for Hodgkin lymphoma.Common among patients with NHL is involvement of the following:Noncontiguous lymph nodes.Waldeyer ring.Epitrochlear nodes.Gastrointestinal tract.Extranodal presentations. (A single extranodal site is occasionally the only site of involvement in patients with diffuse lymphoma.)Bone marrow.Liver (especially common in patients with low-grade lymphomas).Cytologic examination of cerebrospinal fluid may be positive in patients with aggressive NHL. Involvement of hilar and mediastinal lymph nodes is less common than in Hodgkin lymphoma. Mediastinal adenopathy, however, is a prominent feature of lymphoblastic lymphoma and primary mediastinal B-cell lymphoma, entities primarily found in young
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Option Overview
There are different types of treatment for patients with non-Hodgkin lymphoma. Different types of treatment are available for patients with non-Hodgkin lymphoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.For pregnant women with non-Hodgkin lymphoma, treatment is carefully chosen to protect the fetus. Treatment decisions are based on the mother's wishes, the stage of the non-Hodgkin lymphoma, and the age of the fetus. The treatment plan may change as the symptoms, cancer, and pregnancy change.
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Indolent NHL
Indolent non-Hodgkin lymphoma (NHL) includes the following subtypes:Follicular lymphoma.Lymphoplasmacytic lymphoma (Waldenström macroglobulinemia).Marginal zone lymphoma.Splenic marginal zone lymphoma.Primary cutaneous anaplastic large cell lymphoma.Follicular LymphomaFollicular lymphoma comprises 20% of all NHLs and as many as 70% of the indolent lymphomas reported in American and European clinical trials.[1,2,3] Most patients with follicular lymphoma are age 50 years and older and present with widespread disease at diagnosis. Nodal involvement is most common and is often accompanied by splenic and bone marrow disease. Rearrangement of the bcl-2 gene is present in more than 90% of patients with follicular lymphoma; overexpression of the bcl-2 protein is associated with the inability to eradicate the lymphoma by inhibiting apoptosis.PrognosisDespite the advanced stage, the median survival ranges from 8 to 15 years, leading to the
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Aggressive, Noncontiguous Stage II / III / IV Adult NHL
The treatment of choice for patients with advanced stages of aggressive non-Hodgkin lymphoma (NHL) is combination chemotherapy, either alone or supplemented by local-field radiation therapy.The following drug combinations are referred to in this section:ACVBP: doxorubicin + cyclophosphamide + vindesine + bleomycin + prednisone.CHOP: cyclophosphamide + doxorubicin + vincristine + prednisone.CNOP: cyclophosphamide + mitoxantrone + vincristine + prednisone.m-BACOD: methotrexate + bleomycin + doxorubicin + cyclophosphamide + vincristine + dexamethasone + leucovorin.MACOP-B: methotrexate + doxorubicin + cyclophosphamide + vincristine + prednisone fixed dose + bleomycin + leucovorin.ProMACE CytaBOM: prednisone + doxorubicin + cyclophosphamide + etoposide + cytarabine + bleomycin + vincristine + methotrexate + leucovorin.R-CHOP: rituximab, an anti-CD20 monoclonal antibody, + cyclophosphamide + doxorubicin + vincristine + prednisone.Standard Treatment Options for
Chronic Myeloproliferative Neoplasms Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Chronic Myeloproliferative Neoplasms Treatment (PDQ®): Treatment - Patient Information [NCI] - nci_ncicdr0000368374-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Chronic Myeloproliferative Disorders Treatment
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062808-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Childhood Non-Hodgkin Lymphoma Treatment
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Aggressive NHL
Aggressive non-Hodgkin lymphoma (NHL) includes the following subtypes:Diffuse large B-cell lymphoma.Mediastinal large B-cell lymphoma (primary mediastinal large B-cell lymphoma).Follicular large cell lymphoma.Anaplastic large cell lymphoma.Extranodal NK-/T-cell lymphoma.Lymphomatoid granulomatosis.Angioimmunoblastic T-cell lymphoma.Peripheral T-cell lymphoma.Enteropathy-type intestinal T-cell lymphoma.Intravascular large B-cell lymphoma (intravascular lymphomatosis).Burkitt lymphoma/diffuse small noncleaved-cell lymphoma.Lymphoblastic lymphoma.Adult T-cell leukemia/lymphoma.Mantle cell lymphoma.Polymorphic posttransplantation lymphoproliferative disorder.True histiocytic lymphoma.Primary effusion lymphoma.Diffuse Large B-cell LymphomaDiffuse large B-cell lymphoma (DLBCL) is the most common of the NHLs and comprises 30% of newly diagnosed cases. Most patients present with rapidly enlarging masses, often with both local and systemic
Chronic Myeloproliferative Neoplasms Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (10 / 21 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Adult Non-Hodgkin Lymphoma
Adult non-Hodgkin lymphoma is a disease in which malignant (cancer) cells form in the lymph system.